These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

492 related items for PubMed ID: 23992303

  • 1. Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia.
    Yip WK, Choo CW, Leong VC, Leong PP, Jabar MF, Seow HF.
    APMIS; 2013 Oct; 121(10):954-66. PubMed ID: 23992303
    [Abstract] [Full Text] [Related]

  • 2. KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer.
    Mao C, Zhou J, Yang Z, Huang Y, Wu X, Shen H, Tang J, Chen Q.
    PLoS One; 2012 Oct; 7(5):e36653. PubMed ID: 22586484
    [Abstract] [Full Text] [Related]

  • 3. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M.
    Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
    [Abstract] [Full Text] [Related]

  • 4. PIK3CA alterations in Middle Eastern ovarian cancers.
    Abubaker J, Bavi P, Al-Haqawi W, Jehan Z, Munkarah A, Uddin S, Al-Kuraya KS.
    Mol Cancer; 2009 Jul 28; 8():51. PubMed ID: 19638206
    [Abstract] [Full Text] [Related]

  • 5. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.
    Genet Med; 2013 Jul 28; 15(7):517-27. PubMed ID: 23429431
    [Abstract] [Full Text] [Related]

  • 6. High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer.
    Guedes JG, Veiga I, Rocha P, Pinto P, Pinto C, Pinheiro M, Peixoto A, Fragoso M, Raimundo A, Ferreira P, Machado M, Sousa N, Lopes P, Araújo A, Macedo J, Alves F, Coutinho C, Henrique R, Santos LL, Teixeira MR.
    BMC Cancer; 2013 Apr 01; 13():169. PubMed ID: 23548132
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. PI3K pathway dependencies in endometrioid endometrial cancer cell lines.
    Weigelt B, Warne PH, Lambros MB, Reis-Filho JS, Downward J.
    Clin Cancer Res; 2013 Jul 01; 19(13):3533-44. PubMed ID: 23674493
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases.
    Mao C, Wu XY, Yang ZY, Threapleton DE, Yuan JQ, Yu YY, Tang JL.
    Sci Rep; 2015 Feb 02; 5():8065. PubMed ID: 25639985
    [Abstract] [Full Text] [Related]

  • 11. Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.
    Dienstmann R, Serpico D, Rodon J, Saura C, Macarulla T, Elez E, Alsina M, Capdevila J, Perez-Garcia J, Sánchez-Ollé G, Aura C, Prudkin L, Landolfi S, Hernández-Losa J, Vivancos A, Tabernero J.
    Mol Cancer Ther; 2012 Sep 02; 11(9):2062-71. PubMed ID: 22723336
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population.
    Hsieh LL, Er TK, Chen CC, Hsieh JS, Chang JG, Liu TC.
    Clin Chim Acta; 2012 Oct 09; 413(19-20):1605-11. PubMed ID: 22579930
    [Abstract] [Full Text] [Related]

  • 14. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
    Bouali S, Chrétien AS, Ramacci C, Rouyer M, Becuwe P, Merlin JL.
    Oncol Rep; 2009 Mar 09; 21(3):731-5. PubMed ID: 19212633
    [Abstract] [Full Text] [Related]

  • 15. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer.
    Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, Saletti P, Martini M, Cipani T, Marrapese G, Mazzucchelli L, Lamba S, Veronese S, Frattini M, Bardelli A, Siena S.
    PLoS One; 2009 Oct 02; 4(10):e7287. PubMed ID: 19806185
    [Abstract] [Full Text] [Related]

  • 16. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
    Yuen HF, Chan KK, Grills C, Murray JT, Platt-Higgins A, Eldin OS, O'Byrne K, Janne P, Fennell DA, Johnston PG, Rudland PS, El-Tanani M.
    Clin Cancer Res; 2012 Jan 15; 18(2):380-91. PubMed ID: 22090358
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas.
    Schönleben F, Qiu W, Allendorf JD, Chabot JA, Remotti HE, Su GH.
    J Gastrointest Surg; 2009 Aug 15; 13(8):1510-6. PubMed ID: 19440799
    [Abstract] [Full Text] [Related]

  • 19. Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer.
    Kure S, Nosho K, Baba Y, Irahara N, Shima K, Ng K, Meyerhardt JA, Giovannucci EL, Fuchs CS, Ogino S.
    Cancer Epidemiol Biomarkers Prev; 2009 Oct 15; 18(10):2765-72. PubMed ID: 19789368
    [Abstract] [Full Text] [Related]

  • 20. Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma.
    Ollikainen M, Gylling A, Puputti M, Nupponen NN, Abdel-Rahman WM, Butzow R, Peltomäki P.
    Int J Cancer; 2007 Aug 15; 121(4):915-20. PubMed ID: 17471559
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.